Schrödinger secures $85M in financing toward growing drug discovery platform

Medicine Money
The company plans to hire more scientists and developers as it expands its drug discovery teams working on potential new compounds directed at a range of indications. (Getty/utah778)

Schrödinger, a New York-based drug discovery company that uses advanced molecular simulations, has snared $85 million in financing to support its computational platform and expand its pipeline.

The latest round of funding was co-led by the Bill and Melinda Gates Foundation Trust and WuXi AppTec’s Corporate Venture Fund. Also joining in the round of financing was Deerfield Management, Baron, Qiming Venture Partners and GV, formerly Google Ventures.

The company added that it plans to hire more scientists and developers as it expands its drug discovery teams working on potential new compounds directed at a range of indications.

WEBINAR

Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

“The investment will allow us to continue to advance our technology platform to help our users accelerate their work in life sciences and materials design,” Ramy Farid, Ph.D., the company’s chief executive, said in a statement. “We are also excited to expand our drug discovery efforts, leveraging our platform to grow our pipeline and discover new medicines more efficiently.”

In October, Schrödinger and WuXi AppTec unveiled a joint venture dubbed Faxian Therapeutics, which uses the company’s drug discovery platform to identify new targets and create new drugs that will move through WuXi’s CRO services.

Schrödinger is also in partnerships with Takeda and Sanofi. Other companies it has co-founded include Nimbus Therapeutics and Morphic Therapeutic.

Read more on

Suggested Articles

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.

WIRB-Copernicus launched a product aimed at upping the efficiency of clinical research operators at institutions and independent research sites.